Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.
Rouanet
I
I
Peyrière
H
H
Mauboussin
J M
JM
Vincent
D
D
D000280:Administration, Inhalation; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000150:complications / Q000188:drug therapy; D001682:Biological Availability; D003480:Cushing Syndrome / Q000139:chemically induced*; D065607:Cytochrome P-450 Enzyme Inhibitors; D004359:Drug Therapy, Combination; D000068298:Fluticasone; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use
D000730:Androstadienes; D000998:Antiviral Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D005938:Glucocorticoids; D011744:Pyrimidinones; D061466:Lopinavir; D000068298:Fluticasone; D019438:Ritonavir